|
|
 Previous Article | Table of Contents | Next Article 
Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents
of activated cytotoxic T cells with preference for mucosa- associated
lymphoid tissue localization
PC de Bruin, JA Kummer, P van der Valk, P van Heerde, PM Kluin, R Willemze, GJ Ossenkoppele, T Radaszkiewicz and CJ Meijer
Department of Pathology, Free University Hospital, Amsterdam, The
Netherlands.
T-cell non-Hodgkin's lymphomas can be considered the neoplastic equivalents
of immunologically functional, site-restricted T lymphocytes. Little is
known about the occurrence and clinical behavior of T-cell lymphomas that
are the neoplastic equivalents of different functional T-cell subsets.
Here, we investigated the prevalence, preferential site, immunophenotype,
and clinical behavior of the neoplastic equivalents of activated cytotoxic
T cells (CTLs) in a group of 140 nodal and extranodal T-cell lymphomas.
Activated CTLs were shown immunohistochemically with a monoclonal antibody
against granzyme B, a major constituent of the cytotoxic granules of
activated T cells. Granzyme B-positive T-cell lymphomas were mainly found
in mucosa- associated lymphoid tissue (MALT; nose, 63% of the cases;
gastrointestinal tract, 46%; and lung, 33%). Granzyme B-positive cases with
primary localization in MALT were more often associated with angioinvasion
(P = .005), necrosis (P = .002), and histologic characteristics of celiac
disease in adjacent mucosa not involved with lymphoma. Eosinophilia was
more often observed in granzyme B-negative cases (P = .03). Most cases
belonged to the pleomorphic medium- and large-cell group of the Kiel
classification. CD30 expression was more often found in granzyme B-positive
lymphomas of MALT (P = .04), whereas CD56 expression was exclusively found
in nasal granzyme B-positive lymphomas. Immunophenotypically, most of the
cases should be considered as neoplastic equivalents of activated CTLs
based on the presence of T- cell markers on tumor cells. In two cases of
nasal lymphoma, tumor cells probably were the neoplastic counterparts of
natural killer cells. The prognosis of the granzyme B-positive
gastrointestinal T-cell lymphomas was poor but did not differ from granzyme
B-negative gastrointestinal T-cell lymphomas. This indicates that, in
peripheral T- cell lymphomas, site of origin is more important as a
prognostic parameter than derivation of activated CTLs.
Volume 84,
Issue 11,
pp. 3785-3791,
12/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. J. Winrow, D. G. Pankratz, C. R. T. Vibat, T.J. Bowen, M. A. Callahan, A. J. Warren, B. S. Hilbush, A. Wynshaw-Boris, K. W. Hasel, Z. Weaver, et al.
Aberrant recombination involving the granzyme locus occurs in Atm-/- T-cell lymphomas
Hum. Mol. Genet.,
September 15, 2005;
14(18):
2671 - 2684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Bladergroen, C. J. L. M. Meijer, R. L. ten Berge, C. E. Hack, J. J. F. Muris, D. F. Dukers, A. Chott, Y. Kazama, J. J. Oudejans, O. van Berkum, et al.
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Blood,
January 1, 2002;
99(1):
232 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Morice, P. J. Kurtin, A. Tefferi, and C. A. Hanson
Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B
Blood,
January 1, 2002;
99(1):
268 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D F Dukers, M H Vermeer, L H Jaspars, C A Sander, M J Flaig, W Vos, R Willemze, and C J L M Meijer
Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype
J. Clin. Pathol.,
March 1, 2001;
54(3):
224 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Bruno, D. Lautier, A. d. T. d'Orgeix, G. Laurent, and A. Quillet-Mary
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin
Blood,
September 1, 2000;
96(5):
1914 - 1920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Berti, D. Tomasini, M. H Vermeer, C. J. Meijer, E. Alessi, and R. Willemze
Primary Cutaneous CD8-Positive Epidermotropic Cytotoxic T Cell Lymphomas : A Distinct Clinicopathological Entity with an AggressiveClinical Behavior
Am. J. Pathol.,
August 1, 1999;
155(2):
483 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Vermeer, F. A.M.J. Geelen, J. A. Kummer, C. J.L.M. Meijer, and R. Willemze
Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease
Am. J. Pathol.,
April 1, 1999;
154(4):
1203 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chott, W. Haedicke, I. Mosberger, M. Fodinger, K. Winkler, C. Mannhalter, and H.-K. Muller-Hermelink
Most CD56+ Intestinal Lymphomas Are CD8+CD5- T-Cell Lymphomas of Monomorphic Small to Medium Size Histology
Am. J. Pathol.,
November 1, 1998;
153(5):
1483 - 1490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Arnulf, C. Copie-Bergman, M.-H. Delfau-Larue, A. Lavergne-Slove, J. Bosq, J. Wechsler, M. Wassef, C. Matuchansky, B. Epardeau, M. Stern, et al.
Nonhepatosplenic gamma delta T-Cell Lymphoma: A Subset of Cytotoxic Lymphomas With Mucosal or Skin Localization
Blood,
March 1, 1998;
91(5):
1723 - 1731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asadullah, M. Friedrich, W. Sterry, W.-D. Docke, and H.-D. Volk
Granzyme A mRNA Expression in Mycosis Fungoides Progression
Blood,
November 1, 1997;
90(9):
3810 - 3810.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Krenacs, A. Wellmann, L. Sorbara, A. W. Himmelmann, E. Bagdi, E. S. Jaffe, and M. Raffeld
Cytotoxic Cell Antigen Expression in Anaplastic Large Cell Lymphomas of T- and Null-Cell Type and Hodgkin's Disease: Evidence for Distinct Cellular Origin
Blood,
February 1, 1997;
89(3):
980 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
